ARTICLE | Company News
Fabre-Kramer Pharmaceuticals Inc., GlaxoSmithKline deal
February 19, 2007 8:00 AM UTC
Fabre-Kramer granted GSK an exclusive, worldwide license to develop, manufacture and commercialize gepirone ER and follow-on products. The serotonin (5-HT1A) receptor agonist has completed Phase III...